A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2016
At a glance
- Drugs Famciclovir (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Novartis Pharmaceuticals
- 12 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 07 Dec 2007 Status change from recruiting to completed.
- 03 Oct 2005 New trial record.